- Home
- AMWL vs TCRX Comparison
AMWL vs TCRX Comparison
Compare AMWL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMWL | TCRX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 64.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMWL | TCRX |
|---|---|---|
| Price | $5.40 | $0.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $7.58 | ★ $8.50 |
| AVG Volume (30 Days) | 97.4K | ★ 468.8K |
| Earning Date | 02-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $265,023,000.00 | $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.71 | $0.88 |
| 52 Week High | $12.95 | $2.57 |
Technical Indicators
Market Signals| Indicator | AMWL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 38.60 |
| Support Level | $4.18 | $0.91 |
| Resistance Level | $5.08 | $1.04 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 68.38 | 15.43 |
Price Performance
Historical ComparisonAbout AMWL American Well Corporation
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.